

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 39/00		A2	(11) International Publication Number: WO 99/33488 (43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/EP98/08562 (22) International Filing Date: 18 December 1998 (18.12.98) (30) Priority Data: 9727262.9 24 December 1997 (24.12.97) GB		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): DALEMANS, Wilfried, L., J. [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). LAFERRIERE, Craig, Antony, Joseph [CA/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). PRIEELS, Jean-Paul [BE/BE]; SmithKline Beecham Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(74) Agent: DALTON, Marcus, Jonathan, William; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(54) Title: VACCINE			
(57) Abstract <p>The present invention provides vaccine formulations comprising T-independent or polysaccharide conjugate vaccines adjuvanted with an immunostimulatory CpG oligonucleotide.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

Vaccine

The present invention relates to new vaccine formulations, and to methods
5 for their production and their use in medicine.

Immunomodulatory oligonucleotides containing unmethylated CpG dinucleotides ("CpG") are known (WO 96/02555, EP 468520). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. Historically, it was observed that the DNA fraction of BCG could exert an anti-
10 tumor effect. In further studies, synthetic oligonucleotides derived from BCG gene sequences were shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity (Tokunaga, T. et al. *Microbial. Immunol.* 36: 55 (1992)). The central role of the CG motif in
15 immunostimulation was later elucidated in a publication by Krieg (Nature 374 p546 1995). Detailed analysis has shown that the CG motif has sequences that are common in bacterial DNA but are rare in vertebrate DNA.

It is currently believed that this evolutionary difference allows the vertebrate immune system to detect the presence of bacterial DNA (as occurring during an
20 infection) leading consequently to the stimulation of the immune system.

Immunostimulatory activity has been shown for sequences as small as 15 nucleotide bases (Krieg, et al. *Nature* 374: 546 (1995)) and that the CpG motif has to be unmethylated. It has been postulated that the oligo should be in a hexamer setting: purine purine CG pyrimidine pyrimidine, but this is not obligatory.

25 *Streptococcus pneumoniae* is a gram positive bacteria that is pathogenic for humans, causing invasive diseases such as pneumonia, bacteremia and meningitis, and diseases associated with colonisation, such as acute Otitis media. The mechanisms by which pneumococci spread to the lung, the cerebrospinal fluid and the blood is poorly understood. Growth of bacteria reaching normal lung alveoli is
30 inhibited by their relative dryness and by the phagocytic activity of alveolar macrophages. Any anatomic or physiologic derangement of these co-ordinated defenses tends to augment the susceptibility of the lungs to infection. The cell-wall of *Streptococcus pneumoniae* has an important role in generating an inflammatory

response in the alveoli of the lung (Gillespie et al., I&I 65: 3936). The release of cell-wall components occurs at the end of the pneumococcal growth cycle by autolysis due to the synthesis of the protein N-acetyl muramoyl-L-alanine amidase (lytA). DNA will also be released into the infected region upon autolysis of the 5 pneumococci.

In order for the organism to have an effective immune response against invading bacteria, it must have mechanisms to coordinate the type of immune response most likely to stop infection. For intracellular pathogens, the coordination appears to occur between cell mediated or humoral immune responses, and these are 10 controlled by T-cells of the type Th1 and Th2. However, extracellular bacteria frequently employ a polysaccharide either in the form of a capsule or a lipopolysaccharide to protect themselves from the effects of serum complement which can lyse the bacteria, or render them accessible to phagocytes such as macrophage and neutrophils.

15 In this case, the immune response follows another path, the T-independent immune response. The T-independent immune response may be further divided into Type 1 and Type 2. T-independent type 2 antigens possess the characteristics embodied by polysaccharide antigens, including: large molecular weight, repeat antigenic epitopes, ability to activate the complement cascade, poor in vivo 20 degradability and inability to stimulate MHC class II dependent T cell help (Mond et al. Annu Rev Immunol 13:655-92). The Type 1 antigens, unlike the polysaccharides, are mitogenic for B-cells, and are comprised of the lipopolysaccharides (LPS). T-independent Type 2 antigens can not stimulate responses in neonatal mice or CBA/N mice that carry an X-linked immune B-cell 25 defect (xid mice), whereas Type 1 antigens can.

Type 2 antigens induce weaker antibody responses as compared to T-dependent antigens such as proteins. Proteins are able to activate B-cells and induce the secretion of antibody by being processed into peptides and presented on the surface of the B-cell in the context of MHC class II, enabling the B-cell to interact 30 with T-cells and receive additional signals required for maximal B-cell proliferation and maturation. However, whereas oligosaccharides may in some cases associate with MHC class II (Ishioka et al. J. Immunol. 148: 2446-2451) and lipidated

polysaccharides appear to associate with CD1 present on lymphocytes, (Fairhurst, R.M. et al. *Immunology Today* 19: 257 (1998)), there is no known mechanism of presentation for Type 2 antigens to T cells.

Nevertheless, the multiple repeat nature of the polysaccharide polymer 5 antigen can cause cross-linking of receptors on the B-cell surface, leading to B-cell activation by a mechanism not requiring T-cells. Thus polysaccharides are T-independent antigens and they are characterised in animals and human infants by the production of IgM antibodies, and the lack of boosting and immunological memory. It is only adult humans that can produce significant amounts of IgG antibody to 10 most (but not all) polysaccharide antigens. The ability to switch antibody isotype to IgG coincides with the appearance of the complement receptor 2 (CR2) on the B-cells of infants or toddlers between 1.5 to 2 years of age, and this may provide the additional signal required for activation and maturation of B-cells.

The present invention in one aspect provides a vaccine formulation which is 15 capable of raising an immune response to T independent antigen.

Production of IgG antibodies to the capsular polysaccharides of bacteria is essential because the principal mechanism of protection against these bacteria, complement mediated lysis and opsonophagocytosis, are most effective with this antibody isotype (Maslanka et al. *Clin Diag Lab Immunol* 4: 156-67, and Romero-Steiner et 20 al. *Clin Diag Lab Immunol* 4: 415-22).

25 Polysaccharide antigen based vaccines are well known in the art, and four that have been licensed for human use include the Vi polysaccharide of *Salmonella typhi*, the PRP polysaccharide from *Haemophilus influenzae*, the tetravalent meningococcal vaccine composed of serotypes A, C, W135 and Y, and the 23- Valent pneumococcal vaccine composed of the polysaccharides corresponding to serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33. .

30 The latter three vaccines confer protection against bacteria causing respiratory infections resulting in severe morbidity and mortality in infants, yet these vaccines have not been licensed for use in children less than two years of age because they are poorly immunogenic in this age group.

The licensed polysaccharide vaccines listed above have different demonstrated clinical efficacy. The Vi polysaccharide vaccine has been estimated to have an efficacy between 55% and 77% in preventing culture confirmed typhoid fever (Plotkin and Cam, Arch Intern Med 155: 2293-99). The meningococcal C 5 polysaccharide vaccine was shown to have an efficacy of 79% under epidemic conditions (De Wals P, et al. Bull World Health Organ. 74: 407-411). The 23-valent pneumococcal vaccine has shown a wide variation in clinical efficacy, from 0% to 81% (Fedson et al. Arch Intern Med. 154: 2531-2535). The efficacy appears to be related to the risk group that is being immunised, such as the elderly, 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999 10000 10005 10010 10015 10020 10025 10030 10035 10040 10045 10050 10055 10060 10065 10070 10075 10080 10085 10090 10095 10099 10100 10101 10102 10103 10104 10105 10106 10107 10108 10109 10110 10111 10112 10113 10114 10115 10116 10117 10118 10119 10120 10121 10122 10123 10124 10125 10126 10127 10128 10129 10130 10131 10132 10133 10134 10135 10136 10137 10138 10139 10140 10141 10142 10143 10144 10145 10146 10147 10148 10149 10150 10151 10152 10153 10154 10155 10156 10157 10158 10159 10160 10161 10162 10163 10164 10165 10166 10167 10168 10169 10170 10171 10172 10173 10174 10175 10176 10177 10178 10179 10180 10181 10182 10183 10184 10185 10186 10187 10188 10189 10190 10191 10192 10193 10194 10195 10196 10197 10198 10199 10199 10200 10201 10202 10203 10204 10205 10206 10207 10208 10209 10210 10211 10212 10213 10214 10215 10216 10217 10218 10219 10220 10221 10222 10223 10224 10225 10226 10227 10228 10229 10230 10231 10232 10233 10234 10235 10236 10237 10238 10239 10240 10241 10242 10243 10244 10245 10246 10247 10248 10249 10250 10251 10252 10253 10254 10255 10256 10257 10258 10259 10260 10261 10262 10263 10264 10265 10266 10267 10268 10269 10270 10271 10272 10273 10274 10275 10276 10277 10278 10279 10280 10281 10282 10283 10284 10285 10286 10287 10288 10289 10290 10291 10292 10293 10

According to the present invention there is provided a vaccine composition comprising a polysaccharide antigen adjuvanted by an Immunostimulatory oligonucleotide.

The polysaccharide antigen may be unconjugated or conjugated to a carrier 5 protein such that it provides T-helper epitopes.

The oligonucleotides may be DNA or RNA, but preferably contain a hexamer motif: purine purine CpG pyrimidine pyrimidine. More preferably the internucleotide linkage are modified to increase stability of the oligonucleotide.

Preferred modifications are phosphorothioate linkages. The lytA protein involved 10 in the catalytic degradation of the cell wall of pneumococci is produced at the time of autolysis, and is part of the competence induced operon (Mol. Microbiol 29:1125 (1998)). By definition the mRNA encoding lytA will be present in large quantities during synthesis of the lytA protein. Furthermore, the lytA protein contains a phosphoryl choline binding region that contains repeat DNA sequences (Yother and 15 Briles J Bacteriol. 174: 601 (1992)), and which may be found on many other choline binding proteins present in Streptococci. The following CpG sequences were identified from the phosphoryl choline binding regions of lytA and from choline binding protein A (cbpA) (Rosenow et al. Mol. Microbiol 25: 819-829 (1997)).

20

OLIGO 1: GCTACTGGTACG TACATTC AGACGGC TCTT (lytA)

OLIGO 2: ACTATCTAAACGCTAATGGTGCTATGGCGACAGGGATGGCT (cbpA)

25 and may be utilised in the present invention.

The following oligonucleotide immunostimulatory sequences also form preferred embodiments of the invention.

OLIGO 3: TCC ATG ACG TTC CTG ACG TT

30 OLIGO 4: TCT CCC AGC GTG CGC CAT

The CpG and flanking sequences have been underlined, and there is conserved ACGT, ACG and GCG motifs. The sequences derived from the choline binding regions of pneumococcal proteins have two CpG motifs that repeated 10 or 15 nucleotide bases apart, and a motif based on this nucleotide base distance

5 between two CpGs occurs three times and five times respectively in the *lytA* and *CbpA* proteins. However, the published sequences have two CpG motifs that are seven or two nucleotide bases apart.

In one embodiment, when combined with commercially available 23 valent polysaccharide vaccine (Pneumovax, Pasteur Merieux), CpG adjuvantation 10 significantly augmented the immune response (IgG antibody) especially to polysaccharide types 19F and 14 when administered Intramuscularly.

Thus advantageously in an embodiment of the present invention it is possible to enhance the efficacy of a commercially available pneumococcal vaccine. This is particularly important in high risk populations, especially those which have sub-optimal antibody responses to the polysaccharides. Such populations may include, but are not limited to, the elderly, patients with any of the following: splenectomy, congenital asplenia, hyposplenia, sickle cell disease, cyclic neutropenia , drug-induced neutropenia, aplastic anaemia, congenital agammaglobulinemia, hypogammaglobulinemia, selective IgG subclass deficiency, multiple myeloma, 20 chronic lymphocytic leukaemia, lymphoma, HIV infection, multifactorial conditions such as glucocorticoid treatment, malnutrition, cirrhosis of the liver, renal insufficiency, diabetes mellitus, alcoholism, chronic disease, hospitalisation, fatigue, stress, cold exposure, prior respiratory infection, influenza, asthma. It may also include healthy adults such as health workers, military trainees, prisoners, or 25 others including school attendees or travellers wishing to ensure full vaccine coverage.

In a preferred application, the CpG adjuvant is used to augment the response to the polysaccharide vaccine when used as booster in children between 6 and 24 months of age that have received their primary immunisation with a multivalent 30 pneumococcal polysaccharide-protein conjugate. Such vaccines utilised for primary immunisation may also advantageously, be adjuvanted with a CpG oligonucleotide. Accordingly in one embodiment there is provided a method of immunisation of a

patient comprising administering an effective amount of a vaccine according to the invention.

In a second embodiment there is provided a method of boosting an immune response to a subject previously primed to an antigen by administering a T-independent antigen with a CpG immunostimulatory oligonucleotide.

5 CpG adjuvination may be applied, according to the present invention, to other polysaccharide and T-independent antigen based vaccines. These include, but are not limited to, the Vi polysaccharide vaccine against *Salmonella typhi*, the tetravalent meningococcal polysaccharide vaccine (comprising types A, C, W135 and Y), the polysaccharide and modified polysaccharides of group B meningococcus, polysaccharides from *Staphylococcus aureus*, polysaccharides from *Streptococcus agalactiae*, polysaccharides from Mycobacteria, eg 10 *Mycobacterium tuberculosis*, such as mannophosphoinositides trehaloses, mycolic acid, mannose capped arabinomannans, the capsule therefrom and arabinogalactans, polysaccharide from *Cryptococcus neoformans*, the lipopolysaccharides of non-typeable *Haemophilus influenzae*, the lipopolysaccharides of *Moraxella catharralis*, 15 the lipopolysaccharides of *Shigella sonnei*, the lipopeptidophosphoglycan (LPPG) of *Trypanosoma cruzi*, the cancer associated gangliosides GD3, GD2, the tumor associated mucins, especially the T-F antigen, and the sialyl T-F antigen, and the polysaccharide from *HIV* associated polysaccharide that is structurally related to the T-F antigen. Other 20 T independent antigens may be derived from: *Salmonella*, *Cholera*, *Echerichia*, *Chlamydia* and T-independent antigens from *Plasmodium*.

Vaccine preparation is generally described in *Pharmaceutical Biotechnology*, Vol.6! *Vaccine Design - the subunit and adjuvant approach*, edited by Powell and 25 Newman, Plenum Press, 1995. Encapsulation within liposomes is described, for example, by Fullerton, US Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, US Patent 4,372,945 and by Armor et al, US Patent 4,474,757.

The amount of protein in each vaccine dose is selected as an amount which 30 induces an immunoprotective response without significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each

dose will comprise 0.1-1000 µg of polysaccharide or polysaccharide - protein conjugate, preferably 2-100 µg, most preferably 4-40 µg. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination,

5 subjects may receive one or several booster immunisation adequately spaced.

The oligonucleotides utilised in the present invention are typically deoxynucleotides. In a preferred embodiment the internucleotide bond in the oligonucleotide is phosphorodithioate, or more preferably phosphorothioate bond, although phosphodiesters are within the scope of the present invention. Other 10 internucleotide bonds which stabilise the oligonucleotide may be used.

The CpG oligonucleotides utilised in the present invention may be synthesized by any method known in the art (eg EP 468 520) conveniently such oligonucleotides can be synthesized utilising an automated synthesizer. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are 15 described in US 5,663,153, US 5,278,302 and WO 95/26204.

Example 1 - CpG adjuvantation of 23-valent Pneumococcal Polysaccharide in mice

20 Protection against pneumococcal infection is mediated by IgG antibody to the capsular polysaccharide, along with the deposition of complement that renders the bacteria susceptible to killing by neutrophils via opsonophagocytosis. Thus the protective efficacy of the vaccine may be estimated solely on the basis of IgG antibody induction. Groups of 10 mice were immunised once with a commercial

25 23-Valent pneumococcal polysaccharide vaccine at 1/10, 1/50 or 1/250 human dose (57.7, 11.5 and 2.3 µg total polysaccharide respectively), and adjuvanted with CpG (50 µg of oligo 1), CpG + Alum. Following immunization, serum IgG concentrations to the 4 most important serotype polysaccharides (6B, 14, 19F and 23F) were measured by ELISA every 7 days for 4 weeks.

Materials and Methods

The following groups were immunised. (10 balb/c mice per group):

23 Valent at 2.3, 11.5 and 57.5 μ g/dose (1/250, 1/50 and 1/10 human dose)

5 23 Valent + CpG (50 μ g) in the same dose range

23 Valent + CpG + Al(OH)₃ in the same dose range

Components used

Component	Batch	Concentration n μ g/ml	Buffer
23 Valent from Pasteur Mérieux (Pneumovax 23)	95K03-HC56630	1150	Saline
CpG	Oligo 3	5000	H ₂ O
Al(OH) ₃	96A0089	10380	H ₂ O

10

Formulation process

The Pneumovax was diluted in H₂O and 10-fold concentrated 10mM PO₄, 150 mM NaCl pH 6.8 to obtain 2.3, 11.5 or 57.7 μ g of antigen per dose. CpG was added
15 for 30min and for groups containing Al(OH)₃, the formulations were adsorbed for 30 min on either Al(OH)₃ (50 μ g). Thiomersal (50 μ g/ml) was added as preservative.

ELISA

20 There were 10 animals per group, but since bleeds were performed every week, only 5 animals per week were bled. ELISA and opsonophagocytosis were performed on pooled sera.

25 The ELISA was performed to measure murine IgG using the protocol was derived from the WHO Workshop on the ELISA procedure for the quantitation of IgG antibody against *Streptococcus pneumoniae* capsular polysaccharides in human

serum. In essence, purified capsular polysaccharide is coated directly on the microtitre plate. Serum samples are pre-incubated with the cell-wall polysaccharide common to all pneumococcus and which is present in ca. 0.5% in pneumococcal polysaccharides purified according to disclosure (EP72513 B1). Jackson

5 ImmunoLaboratories Inc. reagents were employed to detect bound murine IgG. The titration curves were referenced to internal standards (monoclonal antibodies) modeled by logistic log equation. The calculations were performed using SoftMax Pro software. The maximum absolute error on these results expected to be within a factor of 2. The relative error is less than 30%.

10

Results

IgG isotype antibodies were found against serotypes 14 and 19G, but not against 6B and 23F, and the results for serotype 14 are presented in figure 1. The response

15 was dose dependent with 1/10 human dose giving the highest response, indicating that the IgG response was specific for the polysaccharide. This is unusual since mice normally only produce IgM against pneumococcal polysaccharides. The peak response was on day 14 post immunisation, which is not unusual since T-independent antigens do not induce memory.

20

Additional individual analysis were carried out to determine the variance and the statistical significance (data not shown). The response to 1/10 human dose 23-valent was (statistically) significantly increased when adjuvanted with CpG alone (for Type 19, GMC 0.8 compared to 3.7 μ g/ml $p=0.07$; for Type 14, GMC 0.19 compared

25 to 3.4 μ g/ml, $p=.001$). This was also true for 1/50 and 1/250 doses when measured against type 14. In addition, responses were significantly increased to type 14 when adjuvanted with CpG+Alum.

The highest response was induced when the vaccine was adjuvanted with CpG

30 alone.

Example 2 - Effect of CpG adjuvantation on the immunogenicity of tetravalent Pneumococcal PS-PD conjugates in the infant rat model

The infant rat model was selected since published data showed that the relative 5 immunogenicity of 4 pneumococcal polysaccharide protein conjugates in human infants was more similar to rats than mice. That is 6B < 23F < 14 < 19F for infant rats. Infants rats were selected because their immune system may have developmental immaturity similar to that found in human infants.

10 Infant rats were immunized with Clinical grade lots of Tetravalent pneumococcal polysaccharide-PD^(a) conjugates in a 5-fold dose range and with the adjuvants CpG and AlPO4+CpG. Oligo 1 was used at a dosage of 100 μ g. Animals were first immunized when they were 7 days old and received subsequent immunizations 14 and 28 days later. Serology was performed on samples from day 42 (14 days post 15 III) and 56 (28 days post III).

20 The best adjuvant was CpG alone : it increased geometric mean IgG concentrations and opsonic titers to 6B, 23F and 19F, whereas titers for serotype 14 were comparable to the other adjuvanted preparations. The CpG alone formulation was also able to significantly increase the seroconversion rates to the 6B-PD serotype.

Materials and Methods

Vaccine groups

25 The vaccine lot DSP0401x contains Tetravalent PS-PD Clinical-grade lots D6BPJ208 + D14PDJ202 + D19PJ206 + D23PDJ212. ESP1001 contains Tetravalent PS-LPD lots E6BL040P + E14L66P + E19FL033P + E23FL21P.

Group	Vaccine Lot	Adjuvant	Dose (μ g each PS)
1	none	CpG	-
2	DSP0401x	none	0.1
3	DSP0401x	none	0.5
4	DSP0401x	AlPO4	0.1

Group	Vaccine Lot	Adjuvant	Dose (µg each PS)
5	DSP0401x	AlPO4	0.5
6	DSP0401x	AlPO4	2.5
7	ESPL001	AlPO4	0.1
8	ESPL001	AlPO4	0.5
9	ESPL001	AlPO4	1.25
10	DSP0401x	CpG	0.1
11	DSP0401x	CpG	0.5
12	DSP0401x	CpG/AlPO4	0.1
13	DSP0401x	CpG/AlPO4	0.5

Components used

Component	Batch	Concentration µg/ml	Buffer
Conjugate PD6B	D6BPDJ208	206	NaCl 0.2M pH 6.5
Conjugate PD14	D14PDJ202	186	NaCl 0.2M pH 6.5
Conjugate PD19	D19PDJ206	175	NaCl 0.2M pH 6.5
Conjugate PD23	D23PDJ212	158	NaCl 0.2M pH 6.5
monovalent PD6B	D6BPDD208	100	NaCl 150mM pH 6.1
monovalent PD14	D14PDD202	100	NaCl 150mM pH 6.1
monovalent PD19	D19PDD206	100	NaCl 150mM pH 6.1
monovalent PD23	D23PDD212	96	NaCl 150mM pH 6.1
monovalent LPD6B	E6BL040P	50	NaCl 150mM pH 6.1
monovalent LPD14	E14FL66P	50	NaCl 150mM pH 6.1
monovalent LPD19	E19FL033P	50	NaCl 150mM pH 6.1
monovalent LPD23	E23FL21P	50	NaCl 150mM pH 6.1
Tetraivalent LPD	ESPL001	5/valence	NaCl 150mM pH 6.1
CpG	Oligo 1, WD1001	5000	H ₂ O
AlPO4	97D0045	5040	NaCl 150mM pH 6.1

Formulation Process**Non adsorbed tetravalents.**

5 The four conjugates are diluted in H₂O and 10-fold concentrated NaCl 150mM. Phenoxyethanol (500 µg/ml) is added as preservative.

If CpG is needed, the oligonucleotide is added to the non adsorbed tetravalent. The isotonicity and the dilution when needed are ensured by NaCl.

10 **Adsorbed tetravalents**

The four concentrated, adsorbed monovalents are diluted in H₂O and 10-fold concentrated 150mM NaCl before addition of the of complement of AlPO₄.

15 Phenoxyethanol (500 µg/ml) is added as preservative.

If dilutions are needed, the tetravalents are diluted in AlPO₄ at 1 mg/ml. These diluents are prepared in NaCl 150 mM.

20 If CpG is needed, the oligonucleotide is added to the adsorbed teravalent. The isotonicity is ensured by addition of NaCl 1500 mM and if dilutions are required, diluents of AlPO₄ at 1.3 or 1.8 mg/ml in NaCl are added.

All the formulations are prepared in non siliconized glass vials.

25

Immunisation Protocol

30 Infant rats were randomised to different mothers and were 7 days old when they received the first immunisation. They received subsequent immunisations 14 and 28 days later. Bleeds were performed on day 42 (14 days post III) and 56 (28 days post III). All vaccines were injected s.c., and there were 10 rats per vaccine group.

ELISA

The ELISA was performed to measure rat IgG using the protocol derived from the
5 WHO Workshop on the "ELISA procedure for the quantitation of IgG antibody
against Streptococcus pneumoniae capsular polysaccharides in human serum". In
essence, purified capsular polysaccharide is coated directly on the microtitre plate.
Serum samples are pre-incubated with the cell-wall polysaccharide common to all
pneumococcus and which is present in ca. 0.5% in pneumococcal polysaccharides
10 purified. Jackson ImmunoLaboratories Inc. reagents were employed to detect
bound rat IgG. The titration curves were referenced to the titration curve of a
reference serum modeled by logistic log equation. The calculations were performed
using SoftMax Pro software. The standard sera were calibrated using a method of
corollary response, and the values were demonstrated to correspond to estimations
15 of Ig concentrations found by immunoprecipitation (Ref. 21).

Opsonophagocytosis

The opsonophagocytic assay was performed following the CDC protocol
20 (Streptococcus pneumoniae Opsonophagocytosis using Differntiated HL60 cells,
version 1.1). Modification included the use of in-house pneumococcal strains, and
the phagocytic HL60 cells were replaced by purified human PMN. Rat polyclonal
sera were included as a positive control.

25 Results

Figure 2 shows the geometric mean IgG concentrations elicited against serotype 6B
by the tetravalent combinations described in the materials and methods. For clarity,
the axes are divided by adjuvant and dose. Similar results were obtained against the
30 serotypes 19F and 23F, but type 14 had a more uniform reponse to all adjuvants
and doses.

The biological activity of the pooled antisera from each adjuvant group and dose was measured by opsonophagocytosis. The opsonic activity relative to the concentration of IgG will give an estimate of the functional activity of the antisera.

5 The values, shown in Table 1 show that all adjuvants induce antibody that has approximately the same capacity to opsonise pneumococci. Thus CpG aids in the induction of specific antibody, and increases in antibody concentration correlate with increases in protective efficacy.

10 Conclusion

- AlPO4 (compared to no adjuvant) significantly increases the seroconversion rate, geometric mean IgG concentration, opsonic activity and immunological memory to tetravalent PS-PD.
- The 0.1 µg dose is significantly more immunogenic than 0.5 µg dose for serotypes 6B, 19F and 23F PS-PD conjugates on AlPO4.

20

- IgG concentrations are significantly increased against serotypes 6B, 19F and 23F when the conjugate vaccine is adjuvanted with CpG compared to AlPO4. This is confirmed by increased seroconversion rates and increased opsonophagocytic titres.

Table 1. Relative opsonic activity (Concentration of IgG required for 50% killing of pneumococcus) compared by serotype and adjuvant.

Vaccine	Adjuvant	Dose	Concentration of IgG required for 50% killing				Average by adjuvant
		µg	6B	14	19F	23F	
DSP0401x	none	0,1	0,32	0,30	0,30	0,37	0.26±0.14
		0,5	No Value	0,015	No Value	No Value	
DSP0401x	AlPO4	0,1	0,02	0,31	0,40	0,09	0.20±0.15
		0,5	No Value	0,05	0,22	No Value	
		2,5	No Value	0,32	#VAL	No Value	
ESPL001	AlPO4	0,1	0,08	0,46	No Value	0,22	0.35±0.27
		0,5	0,11	0,71	0,75	0,08	
		1,25	0,10	0,55	0,66	0,20	
DSP0401x	CPG	0,1	0,42	0,15	No Value	0,20	0.24±0.10
		0,5	0,21	0,30	No Value	0,17	
DSP0401x	CPG / AlPO4	0,1	0,27	0,10	No Value	0,21	0.20±0.14
		0,5	No Value	0,10	0,44	0,09	
Average	by serotype		0.19±0.14	0.29±0.20	0.45±0.20	0.18±0.09	

5

Example 3 - Effect of CpG adjuvantation on the immunogenicity of 11-Valent Pneumococcal PS-PD conjugates in the infant rat model

10 Example 2 showed that CpG adjuvantation of conjugate vaccines resulted in fold increases of the order of 5 to 10 times higher than with conventional adjuvants (Aluminium). In order to determine whether these effects were dependent on the Oligo sequence, dosage, or formulation, further experimentation was undertaken.

15 CpG OLIGO 2 was selected and used at a lower dosage, that is 1 and 10 µg. It was also adsorbed onto Al(OH)3, and combined with the conjugate vaccines.

In addition, since the immunological characteristics of each polysaccharide may be different, 11 serotypes were tested.

Material and Methods

5

Table 2. Choice of pneumococcal PS-PD lots

Serotype	1	3	4	5	6B	7F	9V	14	18C	19F	23F
Lot number	017	040	218	024	209	019	222	204	221	207	213

Formulation

10

To examine the effect of different advanced adjuvants, the dosage of conjugate was held constant at 0.1 µg of each polysaccharide, and the adjuvants AlPO₄, Al(OH)₃ and CpG were formulated in different dosages and combinations. In total, 10 different combinations were tested, including no adjuvant at all. These are listed numerically in Table 3 for reference.

15

Preparation of diluents

Two diluents were prepared in NaCl 150 mM/phenoxy

20

A: AlPO₄ at 1mg/ml.

B: CpG on Al(OH)₃ at 200 and 1000 µg/ml respectively. Weight ratio CpG/Al(OH)₃ = 1/5

25

Preparation of adsorbed undecavalent

The eleven concentrated, adsorbed PS-PD monovalents were mixed at the right ratio. The complement of AlPO₄ was added. When needed, CpG (CpG adsorbed on Al(OH)₃) or diluent was added.

30

Preparation of non-adsorbed undecavalent

The eleven PS-PD conjugates were mixed and diluted at the right ratio in NaCl 150 mM pH 6.1, phenoxy. When needed, CpG was added either as a solution (non adsorbed) or as CpG adsorbed on Al(OH)₃.

The formulations for all injections were prepared 18 days before the first administration.

5 **Table 3. Summary Table of Adjuvant Formulations tested with 11-Valent Pneumococcal PS-PD in Infant Rats**

Group	AlPO4	CpG	Al(OH)3	Description
1				None
2	100			AlPO4
3		1		CpG low
4		10		CpG High
5		1	4.5	CpG ads low
6		10	50	CpG ads high
7	100	1		CpG low Conj ads
8	100	10		CpG Hi Conj ads
9	95	1	4.5	CpG&Conj ads low
10	50	10	50	CpG&Conj ads Hi

Immunisation Protocol

10

Infant OFA rats were randomised to different mothers and were 7 days old when they received the first immunisation. They received 2 additional immunisations 14 and 28 days later. A bleed as performed on day 56 (28 days post III). All vaccines were injected s.c., and there were 10 rats per vaccine group.

15

ELISA

The ELISA was performed to as described in example 2.

20 **Opsonophagocytosis**

The opsonophagocytic assay was performed following the CDC protocol (*Streptococcus pneumoniae* Opsonophagocytosis using Differntiated HL60 cells, version 1.1). Modification included the use of in-house pneumococcal strains, and 25 the phagocytic HL60 cells were replaced by purified human PMN. In addition, 3 mm glass beads were added to the microtitre wells to increase mixing, and this allowed reduction of the phagocyte:bacteria ratio which was recommended to be 400.

Results

Tables 4 to 7 below show the geometric mean IgG concentration, seroconversion rate and arithmetic mean opsonophagocytic titre determined for 4 serotypes of pneumococci after immunisation with an 11Valent pneumococcal PS-Protein D conjugate vaccine adjuvanted with different formulations of CpG OLIGO 2. Compared to no adjuvant, 10 µg CpG induced significant higher IgG concentrations for all serotypes. CpG induced significantly higher IgG concentrations than AlPO4 for serotypes 1, 6B, 18C and 19F.

10

For comparison, included in the Tables are the results from Example2 using OLIGO 1. There are no significant differences in the IgG responses induced by the two OLIGO sequences when OLIGO 2 is used at 10 µg. However, OLIGO 2 at 1 µg shows no immunostimulatory effects evidenced in that the induced IgG concentrations are not significantly different from without CpG.

15

Adsorption of OLIGO 2 on Al(OH)3 reduces the immunostimulatory effect, and the induction of antibody is not significantly different than AlPO4 as adjuvant.

TABLE 4

5 Serotype 6B Geometric Mean IgG Concentration, Seroconversion, and Mean Opsonic Titre on Day 28 Post III Immunisation of Infant Rats with 11-Valet PS-PD using Different Adjuvants (And Comparison with Tetravalent Immunisation, Example 2)

Group	Al PO 4 µg	Oligo 1 µg	Oligo 2 µg	6B GMC IgG µg/ml	6B Sero-conversion	6B Opso Titre*	6B GMC IgG µg/ml	6B Sero-conversion	6B Opso Titre*
				Example 2			Example 3		
1				0.047	2/10	12.5	0.004	1/10	<6.25
2	100			0.048	4/10	65	0.019	4/10	<6.25
3			1				0.003	1/10	<6.25
4			10				1.682	10/10	157
	100			0.63	8/10	48			
5			1 µg on Al(OH)3				0.015	6/10	<6.25
6			10 µg on Al(OH)3				0.007	3/10	<6.25
7	100		1				0.029	7/10	<6.25
8	100		10				0.469	9/10	77
	100	100		0.46	7/10	75			
9	95		1 µg on Al(OH)3				0.040	5/10	38
10	50		10 µg on Al(OH)3				0.022	7/10	<6.25

TABLE 5

5 Serotype 14 Geometric Mean IgG Concentration, Seroconversion, and Mean Opsonic Titre on Day 28 Post III Immunisation of Infant Rats with 11-Valent PS-PD using Different Adjuvants (And Comparison with Tetravalent Immunisation, Example 2)

Group	Al PO 4 μ g	Oligo 1 μ g	Oligo 2 μ g	14 GMC IgG μ g/ml	14 Sero-conversion	14 Opso Titre*	14 GMC IgG μ g/ml	14 Sero-conversion	14 Opso Titre*
				Example 2			Example 3		
1				0.046	3/10	64	0.022	3/10	<6.25
2	100			0.99	10/10	88	0.237	8/10	27
3			1				0.035	4/10	<6.25
4			10				0.361	10/10	88
	100			0.66	9/10	295			
5			1 μ g on Al(OH)3				0.093	9/10	<6.25
6			10 μ g on Al(OH)3				0.155	9/10	27
7	100		1				0.134	7/10	<6.25
8	100		10				2.028	10/10	188
	100	100		2.3	10/10	888			
9	95		1 μ g on Al(OH)3				0.140	6/10	138
10	50		10 μ g on Al(OH)3				0.196	10/10	<6.25

TABLE 6

5 Serotype 19F Geometric Mean IgG Concentration, Seroconversion, and Mean Opsonic Titre on Day 28 Post III Immunisation of Infant Rats with 11-Valent PS-PD using Different Adjuvants (And Comparison with Tetravalent Immunisation, Example 2)

Group	Al PO 4 μ g	Oligo 1 μ g	Oligo 2 μ g	19F GMC IgG μ g/ml	19F Sero-conversion	19F Opso Titre*	19F GMC IgG μ g/ml	19F Sero-conversion	19F Opso Titre*
				Example 2			Example 3		
1				0.04	2/10	64	0.021	2/10	<6.25
2	100			1.07	9/10	367	0.222	7/10	79
3			1				0.015	3/10	<6.25
4			10				4.287	10/10	415
		100		12.	10/10	>1600			
5			1 μ g on Al(OH)3				0.417	9/10	32
6			10 μ g on Al(OH)3				1.612	9/10	94
7	100		1				0.441	10/10	135
8	100		10				9.475	10/10	>1600
	100	100		11.0	10/10	>1600			
9	95		1 μ g on Al(OH)3				0.438	9/10	377
10	50		10 μ g on Al(OH)3				0.258	7/10	165

TABLE 7

5 Serotype 23F Geometric Mean IgG Concentration, Seroconversion, and Mean Opsonic Titre on Day 28 Post-III Immunisation of Infant Rats with 11-Valet PS-PD using Different Adjuvants (And Comparison with Tetravalent Immunisation, Example 2)

Group	Al PO 4 μ g	Oligo 1 μ g	Oligo 2 μ g	23F GMC IgG μ g/ml	23F Sero-conversion	23F Opso Titre*	23F GMC IgG μ g/ml	23F Sero-conversion	23F Opso Titre*
				Example 2			Example 3		
1				0.06	2/10	<6.25	0.152	3/10	<6.25
2	100			0.29	10/10	70	0.56	8/10	<6.25
3			1				0.114	4/10	<6.25
4			10				1.305	9/10	192
		100		2.0	10/10	454			
5			1 μ g on Al(OH)3				0.28	7/10	<6.25
6			10 μ g on Al(OH)3				0.107	2/10	<6.25
7	100		1				0.243	4/10	<6.25
8	100		10				1.545	9/10	862
	100	100		1.1	10/10	265			
9	95		1 μ g on Al(OH)3				0.255	3/10	44
10	50		10 μ g on Al(OH)3				0.331	6/10	<6.25

10

Example 5 Influence of CpG on Boosting with Polysaccharide after Priming with Polysaccharide-Conjugate Vaccines, and on Priming with Polysaccharide.

15 The previous examples have demonstrated the ability of CpG to adjuvant the immune response to T-independent antigens, and to T-independent antigens coupled to a protein carrier. There remained to be considered whether CpG could adjuvant a memory response elicited by boosting with a T-independent antigen after priming with T-dependent antigen. It was of further interest to determine if CpG could act 20 to induce priming by a T-independent antigen.

To determine these effects, mice were primed with either pneumococcal polysaccharide, or CpG adjuvanted pneumococcal polysaccharide, or Protein D conjugate pneumococcal polysaccharide.

5

Immunisation Protocol

Six to 8 week old balb/c mice were immunise subcutaneously with the vaccine formulations described below. The dosage was 1 μ g per polysaccharide for both 10 conjugated and non-conjugated formulations. A test bleed was performed 14 days later to measure IgG concentrations. After 56 days, another test bleed was performed, and then a booster vaccination was given, and a final test bleed was performed 14 days later, that is 70 days after the first immunisation.

Group	Prime	Boost
1	Saline	Conjugate
2	PS	PS
3	PS/Cp	PS
4	PS	Conjugate
5	PS/Cp	Conjugate
6	Conjug	PS
7	Conjug	PS/CpG
8	Conjug	Conjugate

15

Components used

Component	Batch	Conc μ g/ml	Buffer	Adsorption	PS conc after adsorption μ g/ml	Buffer after adsorption
PS6b	6b/24	2000	NaCl 150mM			
PS14	14/19	2000	NaCl 150mM			
PS19	19f/26b	2000	NaCl 150mM			
PS23	23f/29	2000	NaCl 150mM			
Conjugate PDPS6B	D6BPDJ 209			MBSP9801	100	NaCl 150mM pH 6.1/phenoxy

Component	Batch	Conc μg/ml	Buffer	Adsorption	PS conc after adsorptio n μg/ml	Buffer after adsorption
Conjugate PDPS14	D14PDJ 204			MBSP9801	100	NaCl 150mM pH 6.1/phenoxy
Conjugate PDPS19	D19PDJ 207			MBSP9801	100	NaCl 150mM pH 6.1/phenoxy
Conjugate PDPS23	D23PDJ 213			MBSP9801	100	NaCl 150mM pH 6.1/phenoxy
CpG	Oligo 1	5000	H2O			
St Pn AlPO4 diluent	97D004 5				1000	NaCl 150mM pH 6.1/phenoxy

Formulation process

Preparation of 4 concentrated, adsorbed monovalents (PS-PD conjugates)

5

The concentrated, adsorbed monovalents were prepared according the procedure described above in Example 2.

Preparation of tetravalent (PS-PD conjugates)

10

The four concentrated, adsorbed monovalents were mixed at the right ratio (1μg of each valence/dose) and diluted in NaCl pH6.1. The complement of AlPO4 (10μg/dose) was added as a diluent at 1mg/ml in NaCl 150mM pH6.1 containing 5mg/ml of phenoxyethanol.

15

Preparation of non-conjugated, non-adsorbed, tetravalent with or without CpG (free PS)

The four free PS were mixed at the right ratio (1μg of each valence/dose) and diluted in NaCl pH6.1. When needed, CpG (100μg/dose) was added. Five mg/ml of phenoxyethanol were added as preservative.

The formulations for both injections were prepared 6 days before the first administration in non siliconized glass vials.

Formulation process

5

Preparation of 4 concentrated, adsorbed monovalents (PS-PD conjugates)

The concentrated, adsorbed monovalents were prepared according the procedure describe above.

10 Preparation of tetravalent (PS-PD conjugates)

The four concentrated, adsorbed monovalents were mixed at the right ratio (1 μ g of each valence/dose). The complement of AlPO₄ (10 μ g/dose) was added as a diluent at 1mg/ml in NaCl 150mM pH6.1 containing 5mg/ml of phenoxyethanol.

15

Preparation of non conjugated, non adsorbed, tetravalent with or without CpG (free PS)

20 The four free PS were mixed at the right ratio (1 μ g of each valence/dose) and diluted in NaCl pH6.1. When needed, CpG was added. Five mg/ml of phenoxyethanol were added as preservative.

The formulations for both injections were prepared 6 days before the first administration in non siliconized glass vials.

25

ELISA

The ELISA was performed as described in Example 1

Results

The results of this experiment are the priming and the boosting. The results of the 5 priming were consistent with previous observations (Example 1) in that increased seroconversion and higher IgG concentrations were found in mice that were immunised with CpG adjuvanted polysaccharide compared to plain polysaccharide. As was found in Example 1, the increases in type 14 IgG concentration with CpG adjuvantation are statistically significant compared to PS alone, and the increases 10 for type 19F approach significance. However, the IgG concentrations with CpG adjuvantation were not as high as observed in Example 1. To explain this difference, only two differences in the experiments were made, the valency of the vaccine (23 valent versus 4 valent) and the route of immunisation (intramuscular versus subcutaneous). Since the reduction of valence is not expected to decrease 15 immunogenicity, the evidence indicates that the route of immunisation is important for optimal CpG adjuvantation of T-independent antigens. This is consistent with a recent publication which disclosed a failed attempt to use CpG adjuvantation of a plain polysaccharide vaccine. The route of immunisation employed was interperitoneal (Threadgill et al Vaccine 1998 Vol 16(1) p76).

20

	Seroconversion	GMC
PS 14	2/20*	0.07
PS14/CpG	12/20* δ	0.15
Conjugate	24/30 δ	1.04
PS19F	1/20 ξ	0.08
PS19F CpG	4/20 ξ ϖ	0.10
Conjugate	22/30 ϖ	0.35

* p = 0.001 Fisher's exact test

δ p = 0.11 Fisher's exact test

ξ p = 0.17 Fisher's exact test

25 ϖ p < 0.001 Fisher's exact test

In the second part of this experiment, animals primed with either PS, PS/CpG or conjugate vaccine, were boosted with PS, or with PS/CpG or with conjugate. To normalise the data for comparison, the fold increase in IgG was determined 14 days 5 after the booster was given, and the number of animal showing an increase in antibody concentration were counted as responders.

Prime	Boost	Geometric Fold Increase	Positive responders
PS	PS	1.7*	5/10
PS/CpG	PS	2.8*	6/10
Conjugate	PS	0.78\x	1/10 δ
Conjugate	PS/CpG	1.7\x	6/10 δ
Conjugate	Conjugate	4.2	7/10

* p = 0.09 Student's t-test
10 \x p = 0.12 Student's t-test
 δ p = 0.03 Fisher's exact test

Discussion

15 This example confirms the results presented in Example 1, but has revealed that the mode of immunisation may be important for optimal immunity. In an extension of the experiment to boosting and memory, two interesting characteristics of CpG adjuvantation are demonstrated. The first is that priming with PS adjuvanted with CpG leads to a higher fold increase upon boosting with polysaccharide, and there is 20 a trend towards statistical significance. This would indicate that CpG was able to induce better memory. The second characteristic is that CpG can adjuvant a memory response induced by polysaccharide in animals primed with conjugate vaccine.

Conclusions

CpG is able to induce in mice an antibody isotype switch against non-conjugated
5 polysaccharides. The magnitude of the IgG response is higher with CpG.

Claims

1. A formulation comprising a CpG oligonucleotide and T-independent type 1 or type 2 antigens or polysaccharide conjugate antigen.

5

2. A formulation as claimed in claim 1, wherein the antigen is selected from the unconjugated Streptococcus Pneumoniae Polysaccharide, unconjugated meningococcal Polysaccharide, unconjugated Salmonella polysaccharide, unconjugated group A or group B streptococcal polysaccharides, polysaccharides from mycobacteria unconjugated Pseudomonas mucoid polysaccharide or TF-antigens derived from HIV, or lipopolysaccharides or detoxified lipopolysaccharides derived from Salmonella, Cholera, Echerichia, Neisseria, Chlamydia, Shigella, Pertussis, Haemophilus, or Pseudomonas, or T-independent antigens from Plasmodium.

10

3. A formulation as claimed in claim 1 & 2 wherein the CpG deoxyribo- or ribo-oligonucleotide has an internucleotide bond, selected from phosphodiesters, phosphorodithioate and phosphorothioate.

15

4. A formulation comprising a CpG deoxyribo or ribo-oligonucleotide sequence claimed in claim 2 which contains two CpG sequences that are separated by seven or more nucleotide base pairs.

5. A deoxyribo or ribo-oligonucleotide sequence claimed in claim 4 which contains two CpG sequences that are separated by 10 to 15 nucleotide base pairs.

6. A formulation as claimed herein wherein the CpG oligonucleotide is selected from the group:

30 GCTACTGGTACG TACATTC AGACGGC TCTT
ACTATCTAACGCTAATGGTGCTATGGCGACAGGATGGCT

TCC ATG ACG TTC CTG ACG TT

TCT CCC AGC GTG CGC CAT

7. A vaccine composition as claimed herein for use in medicine.

5

8. A method of inducing an immune response to T independent type 1 or type 2 antigen or a polysaccharide conjugate antigen, said method comprising administering a safe and effective amount of a formulation as claimed herein to a patient.

1/2




Fig. 1 anti-PS14 IgG levels (days 7-28) in sera B45124a

2/2




Fig.2 B45124a